ストックスクリーナーアプリを入手
0.9257
3.41%
0.0305
アフターアワーズ：
.92
-0.0057
-0.62%
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World
Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.
Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia
Tempest Therapeutics amends rights agreement - Investing.com India
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
William Blair Has Negative Estimate for TPST FY2024 Earnings - Defense World
Research Analysts Offer Predictions for TPST FY2024 Earnings - Defense World
500: Something went wrong - Investing.com Canada
TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com
HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks
TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada
Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com India
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire
Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
Stock Region Penny Picks - substack.com
Tempest Therapeutics Inc [TPST] Stock trading around $1.10 per share: What’s Next? - The DBT News
Tempest Therapeutics Inc [NASDAQ: TPST] Sees Decrease in Stock Value - Knox Daily
Tempest Therapeutics shares retain Buy rating post Roche deal - Investing.com
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a -18.52 Decrease, Closing at 1.10 - The Dwinnex
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Fluctuations - The InvestChronicle
TPST’s price-to-free cash flow ratio: What it means for investors - US Post News
Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study - XM
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell - Marketscreener.com
Tempest stock gains on Roche collaboration (NASDAQ:TPST) - Seeking Alpha
Tempest Therapeutics partners with Roche on cancer trial - Investing.com
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - ForexTV.com
Tempest Therapeutics, Inc Enters into Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd. to Which Roche Will Supply Roche?S Atezolizumab - Marketscreener.com
Tempest Extends Limited Duration Stockholder Rights Plan - GlobeNewswire
Tempest Announces Agreement with Roche to Support - GlobeNewswire
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):